Key result
Terfenadine at 10 µM caused a 100% incidence of non-Torsades de Pointes-like ventricular tachycardia/fibrillation in experimental models, driven by I(Na) blockade rather than QT prolongation.
Why the study?
Does terfenadine induce ventricular tachycardia/fibrillation through QT prolongation and Torsades de Pointes or via other mechanisms in in vitro cardiac models?
Does terfenadine induce ventricular tachycardia/fibrillation through QT prolongation and Torsades de Pointes or via other mechanisms in in vitro cardiac models?
Terfenadine-induced cardiac death may be primarily driven by non-TdP-like VT/VF caused by sodium channel blockade and conduction slowing, rather than hERG blockade and QT prolongation.
Answers are grounded in this paper and cite their sources.
Terfenadine cardiotoxicity may primarily involve sodium channel blockade; challenges hERG/QT-centric models and leaves open human translation.
BACKGROUND AND PURPOSE: Terfenadine has been reported to cause cardiac death. Hence, we investigated its pro-arrhythmic potential in various in vitro models. EXPERIMENTAL APPROACH: Pro-arrhythmic effects of terfenadine were investigated in rabbit isolated hearts and left ventricular wedge preparations. Also, using whole-cell patch-clamp recording, we examined its effect on the human ether-à-go-go-related gene (hERG) current in HEK293 cells transfected with hERG and on the I(Na) current in rabbit ventricular cells and human atrial myocytes. KEY RESULTS: Terfenadine concentration- and use-dependently inhibited I(Na) in rabbit myocytes and in human atrial myocytes and also inhibited the hERG. In both the rabbit left ventricular wedge and heart preparations, terfenadine at 1 µM only slightly prolonged the QT- and JT-intervals but at 10 µM, it caused a marked widening of the QRS complex, cardiac wavelength shortening, incidences of in-excitability and non-TdP-like ventricular tachycardia/fibrillation (VT/VF) without prolongation of the QT/JT-interval. At 10 µM terfenadine elicited a lower incidence of early afterdepolarizations versus non- Torsades de Pointes (TdP)-like VT/VF (100% incidence), and did not induce TdPs. Although the concentration of terfenadine in the tissue-bath was low, it accumulated within the heart tissue. CONCLUSION AND IMPLICATIONS: Our data suggest that: (i) the induction of non-TdP-like VT/VF, which is caused by slowing of conduction via blockade of I(Na) (like Class Ic flecainide), may constitute a more important risk for terfenadine-induced cardiac death; (ii) although terfenadine is a potent hERG blocker, the risk for non-TdP-like VT/VF exceeds the risk for TdPs; and (iii) cardiac wavelength (λ) could serve as a biomarker to predict terfenadine-induced VT/VF.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2012) studied Terfenadine-induced pro-arrhythmia. Terfenadine was evaluated on Incidence of non-Torsades de Pointes-like ventricular tachycardia/fibrillation. Terfenadine at 10 µM caused a 100% incidence of non-Torsades de Pointes-like ventricular tachycardia/fibrillation in experimental models, driven by I(Na) blockade rather than QT prolongation.
Synapse has enriched 10 related papers. Consider them for comparative context: